Biomerica, Inc. announced that its Fortel Ulcer Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory approval enables Biomerica to introduce its rapid point-of-care test for Helicobacter pylori (H. pylori) infection across the UAE, where gastrointestinal diseases are a growing public health concern. The Fortel Ulcer Test is a simple, quick, and user-friendly diagnostic tool that detects antibodies to H. pylori, delivering accurate results in just 10 minutes.
H. pylori is a bacterium known to cause peptic ulcer disease, dyspepsia, and gastric cancer, with approximately 80% of gastric cancer cases attributed to this infection. The World Health Organization (WHO) has classified H. pylori as a Class 1 carcinogen and listed it among the top antibiotic-resistant bacterial threats. In the UAE, local studies estimate H. pylori infection rates exceeding 50%, highlighting a major global and regional health threat.
This approval further expands Biomerica’s growing footprint in the Middle East, following successful regional launches of other diagnostic products. The company is collaborating with UAE-based distributors and healthcare providers to make the Fortel Ulcer Test available throughout the country. CEO Zack Irani stated that the test empowers healthcare providers to rapidly detect H. pylori infection and take timely action to prevent serious gastrointestinal diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.